Repurposing existing drugs: identification of irreversible IMPDH inhibitors by high-throughput screening

Albertus Eka Yudistira Sarwono\textsuperscript{a*,b}, Shinya Mitsushashi\textsuperscript{a,b,\#}, Mohammad Hazzaz Bin Kabir\textsuperscript{c}, Kengo Shigetomi\textsuperscript{a}, Tadashi Okada\textsuperscript{d,\#}, Fumina Ohsaka\textsuperscript{d}, Satoko Otoguro\textsuperscript{d}, Katsumi Maenaka\textsuperscript{d}, Makoto Igarashi\textsuperscript{c}, Kentaro Kato\textsuperscript{c} and Makoto Ubukata\textsuperscript{a} \textsuperscript{\dagger}

\textsuperscript{a}Division of Applied Bioscience, Graduate School of Agriculture, Hokkaido University, Sapporo, Japan; \textsuperscript{b}Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX, USA; \textsuperscript{c}National Research Center for Protozoan Diseases, Obihiro University of Agriculture and Veterinary Medicine, Obihiro, Japan; \textsuperscript{d}Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan; \textsuperscript{\#}Division of Neurology, Respiratory, and Metabolism, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Kiyotake, Miyazaki, Japan

ABSTRACT
Inosine 5'-monophosphate dehydrogenase (IMPDH) is an essential enzyme for the production of guanine nucleotides. Disruption of IMPDH activity has been explored as a therapeutic strategy for numerous purposes, such as for anticancer, immunosuppression, antiviral, and antimicrobial therapy. In the present study, we established a luciferase-based high-throughput screening system to identify IMPDH inhibitors from our chemical library of known bioactive small molecules. The screening of 1400 compounds resulted in the discovery of three irreversible inhibitors: disulfiram, bronopol, and ebselen. Each compound has a distinct chemical moiety that differs from other reported IMPDH inhibitors. Further evaluation revealed that these compounds are potent inhibitors of IMPDHs with \( k_{on} \) values of 0.7 \( \times 10^4 \) to 9.3 \( \times 10^5 \) M\(^{-1}\) s\(^{-1}\). Both disulfiram and bronopol exerted similar degree of inhibition to protozoan and mammalian IMPDHs. Ebselen showed an intriguing difference in mode of inhibition for different IMPDHs, with reversible and irreversible inhibition to each Cryptosporidium parvum IMPDH and human IMPDH type II, respectively. In the preliminary efficacy experiment against cryptosporidiosis in severe combined immunodeficiency (SCID) mouse, a decrease in the number of oocyst shed was observed upon the oral administration of disulfiram and bronopol, providing an early clinical proof-of-concept for further utilization of these compounds as IMPDH inhibitors.

Introduction
Inosine 5'-monophosphate dehydrogenase (IMPDH) is an attractive drug target due to its essential role in cellular purine nucleotide biosynthesis. It catalyzes the conversion of IMP to xanthosine monophosphate (XMP), which will be eventually converted to guanosine monophosphate (GMP) for the DNA biosynthesis pathway.

Inhibition of Cryptosporidium parvum IMPDH (CpIMPDH) of the pathogenic protozoa C. parvum has been proposed as an antiprotozoal therapeutic strategy against the infection. The enzyme plays an important role in the streamline salvage purine nucleotide biosynthesis of the protozoa. Therefore, inhibition of the enzyme resulted in a detrimental effect to the protozoan growth. In human, IMPDH has two isoenzymes, type I and type II. Generally, human IMPDH type I (hIMPDH I) is a ubiquitous enzyme and expressed by various tissues in low level, while hIMPDH II is expressed in a rapidly multiplying cells. Inhibition of hIMPDH II, in particular, has been sought after, due to its role as a chemotherapeutic target for various purposes, such as anticancer, immuno-suppressive, and antiviral therapy\textsuperscript{1-8}. Therefore, this study was aimed to discover novel inhibitors for CpIMPDH and hIMPDH II, representatives of microbial and mammalian IMPDH, respectively.

In the effort to discover new inhibitors, it is important to not only focusing on novel bioactive compounds but to also in repurposing existing compounds to a novel molecular target. Evidently, repurposing of a known bioactive compound, particularly the ones with established pharmacological properties, could significantly alleviate the intensive labor and enormous financial burden of the conventional drug development processes\textsuperscript{9-11}. Furthermore, the introduction of robotics systems into the field of medicinal chemistry, especially as an automatic solution handlings system, has further accelerated the above-mentioned lengthy process. These mechanizations provide scientists with the capability to carry out bioassays with a much higher throughput.

In this study, the discovery and the characterization of three irreversible IMPDH inhibitors: ebselen, disulfiram, and bronopol, were discussed. The inhibition kinetic parameters were then tested for CpIMPDH and hIMPDH II. Overall, this study provided a new perspective of the available classes of irreversible IMPDH inhibitors. The variation in the inhibitor moiety could be beneficial for the discovery of new IMPDH inhibitors.
the future design and development of more potent and selective IMPDH inhibitors.

**Materials and methods**

**Molecular methods**

The coding sequence of CpIMPDH was amplified by PCR using primer sets 5’-TTTTGGATCCTCAACATGGTGACA-3’ and 5’-TTTTGAATTCCTATTTACT-ATAATT-3’. The PCR product was cloned into pCR2.1-TOP vector (Invitrogen Japan KK, Tokyo, Japan), and the complete gene sequence was confirmed using ABI PRISM 3100 Genetic Analyzer (Applied Biosystems, Tokyo, Japan). CpIMPDH gene was digested by BamHI and EcoRI, and inserted into a pGEX-6P-2 plasmid (GE Healthcare Bio-Science Corp., Amersham, UK). The plasmid was then transformed to E. coli BL21 (DE3) (Wako Pure Chemical Ind., Ltd., Osaka, Japan).

The plasmid of hIMPDH II was a generous gift from Prof. Lizbeth Hedstrom, Brandeis University, USA. The plasmid was transformed in the same manner as for CpIMPDH.

**Expression and purification of recombinant IMPDH**

Cells carrying previously described plasmids were grown overnight at 30°C in 50ml 2xYT broth containing 100μg/ml ampicillin. Then the broth was subcultured to 700ml of medium containing a final concentration of 1 mM isopropyl-1-thio-β-galactopyranoside (Sigma-Aldrich Japan, Tokyo, Japan) and 100μg/ml ampicillin. After 5h incubation at 25°C, cells were harvested by centrifugation, washed with PBS solution, and stored frozen at −80°C until usage. The cell was later thawed on ice, suspended with 50mM Tris-HCl pH 8.0 containing 5mM EDTA (Sigma-Aldrich Japan), and 2μg/ml leupeptin, then sonicated.

The cell lysate was centrifuged, the supernatant was applied to Glutathione Sepharose 4B (GE Healthcare Bio-Science Corp.), then mixed gently overnight. The unbound proteins were washed with 30mM Tris-HCl pH 8.0 containing 1mM MgCl₂, 150mM NaCl, 1mM DTT, 0.5mM benzamidine (Sigma-Aldrich Japan), and 2μg/ml leupeptin. GST-tag was cleaved using PreScission protease (GE Healthcare Bio-Science Corp.) according to manufacturer manual. The enzyme fraction was isolated and applied to Glutathione Sepharose 4B (GE Healthcare Bio-Science Corp.), then mixed gently overnight. The unbound proteins were washed with 30mM Tris-HCl pH 8.0 containing 1mM MgCl₂, 150mM NaCl, 1mM DTT, 0.5mM benzamidine (Sigma-Aldrich Japan), and 2μg/ml leupeptin. GST-tag was cleaved using PreScission protease (GE Healthcare Bio-Science Corp.) according to manufacturer manual. The enzyme fraction was isolated and dialyzed overnight with 30mM Tris-HCl buffer (pH 7.5) containing 1mM MgCl₂, 1mM DTT, 0.5mM benzamidine, and 50% glycerol. All purification processes were carried out at 4°C unless stated otherwise. The purified IMPDHs were then supplemented with 10μg/ml leupeptin and stored at −20°C until usage.

**Establishment and validation of high-throughput screening system**

The high-throughput screening (HTS) assay was established using NAD(P)H-Glo Assay Kit (Promega, Madison, WI). Briefly, a substrate solution containing 50mM Tris-HCl pH 8.0, 200mM KCl, 0.1mg/ml BSA, 1.6mM β-NAD⁺ (Oriental Yeast Co., Tokyo, Japan), 100μM IMP (Sigma-Aldrich Japan), and assay kit was added to white 384-well plates. Mycophenolic acid (APAC Pharmaceutical LLC, Hangzhou, China), a known IMPDH inhibitor, or compounds from the Pharmakon repositioning library of 1570 off-patent US Food and Drug Administration (FDA)-approved compounds (Microsource Discovery Systems, Inc., CT) were also added to the wells. The reaction was started by addition of enzyme solution containing 50mM Tris-HCl pH 8.0, 0.1mg/ml BSA, and CpIMPDH. The reaction was carried out at 30°C for 30min in dark. Solution handling was carried out using Mosquito LCP (TTP LabTech Ltd., Melburn, UK) and Multidrop Combi (Thermo Scientific, Waltham, MA). The production of NADH was monitored by luminescence measurement using either VERITAS Microplate Luminometer (Turner Biosystems, Sunnyvale, CA), or EnSpire Multimode Reader (Perkin-Elmer, Waltham, MA).

The counter assay was carried out by directly incubating assay kit, the library compounds, and an appropriate amount of NADH. The produced chemiluminescence was monitored.

The half maximal inhibitory concentration (IC₅₀) values were calculated by plotting the recorded NADH yield against log of compound concentration in GraFit ver. 7 (Erithacus Software, West Sussex, UK). All screening assays in this study were conducted with 0.5% DMSO as vehicle and library compound concentration of 10μM unless stated otherwise.

**Kinetics of IMPDH inhibition by hit compounds**

**Irreversible inhibition**

Standard IMPDH assay solution contains 50 mM Tris-HCl pH 8.0, 100 mM KCl, 3 mM EDTA, 0.1 mg/ml BSA, and an appropriate amount of inhibitor. Substrate concentrations are 500μM NAD⁺ and 250μM IMP for CpIMPDH, 100μM NAD⁺ and 250μM IMP for hIMPDH II. The reaction was started by the addition of an appropriate amount of enzyme. The activity of the enzyme was measured by monitoring NADH production in absorbance at 340 nm.

The exponential inactivation was quantified by fitting the decay progress curve to Equation (1)²,¹²,¹³:

\[ \frac{R_t - R_0}{V_0} = \frac{k_{obs}}{k_{obs}} \left(1 - e^{-k_{obs} t}\right) \]  

where \( R_t \) is the absorbance at time \( t \), \( R_0 \) is the initial absorbance at time \( 0 \), \( V_0 \) is the initial reaction rate, and \( k_{obs} \) is the observed rate constant of enzyme inactivation. Acquired \( k_{obs} \) values then fitted into Equation (2) to obtain \( k_{on} \) value:

\[ k_{obs} = \frac{k_{on} [I]}{1 + [S] K_m} \]  

where \( k_{on} \) is the apparent second-order rate constant for IMPDH inactivation, \([I]\) is inhibitor concentration, \([S]\) is IMP concentration, and \( K_m \) is Michaelis–Menten constant for IMP.

Plot fitting of the inhibitory study was carried out using GraphPad Prism 7.0 (GraphPad Software, San Diego, CA). Values of inhibitory activity were expressed as mean ± SD for two independent experiments.

**Reversible inhibition**

Reversible inhibition parameter was measured by monitoring the formation of NADH in various substrate concentrations in the presence and absence of inhibitor. The assay was carried out with standard IMPDH assay solution as mentioned in Irreversible inhibition. Data were fitted into noncompetitive inhibition (Equation (3)) or mixed-model inhibition (Equation (4)):

\[ V = \frac{V_m [S]}{K_m \left(1 + \frac{[S]}{K_s}ight) + [S] \left(1 + \frac{[I]}{K_i}\right)} \]  

\[ V = \frac{V_m [S]}{K_m \left(1 + \frac{[S]}{K_s}ight) + [S] \left(1 + \frac{[I]}{K_i}\right)} \]  

where \( V \) is reaction velocity, \( V_m \) is the maximal velocity, \([S]\) is substrate concentration, \( K_m \) is the Michaelis–Menten constant for the substrate, \( K_i \) is inhibition constant when the inhibitor shows equal
affinity to free enzyme and enzyme-substrate complex, $K_{ii}$ is the slope inhibition constant, and $K_{ii}$ is the intercept inhibition constant.

Plot fitting of the inhibitory study was carried out using GraphPad Prism 7.0. Values of inhibitory activity were expressed as mean ± SD for two independent experiments.

**Enzyme-Inhibitor dockings and C. parvum in vivo inhibitory studies**

Experiment information available as supplementary material.

**Results**

**HTS of chemical library compounds**

The chemiluminescence-based HTS system enables assays to be carried out with a low microliter volume but still produce robust and selective signal. Signal-to-noise ratio was high, with experimental signal up to 3-magnitudes higher than those of empty wells. The developed system has an average $Z'$-factor value of 0.7 from three independent experiments (0.71, 0.7, and 0.66), indicating an excellent assay system for screening (Figure S1)$^{14}$. Using this system, a collection of 1400 known bioactive compounds was screened for any CpIMPDH inhibitory activity. The primary screening was conducted with a compound concentration of 10 $\mu$M, and resulted in the identification of 32 compounds as hits based on a standard deviation offset. To exclude false-positives, a concentration–response curve test was subsequently carried out. A counter assay as the secondary screening was carried out to exclude any reductase–luciferase inhibitors. Final hits from the screening system comprised of four compounds (0.3%) (Figure 1(A,B)). Finally, three compounds were chosen to be analyzed in this study: ebselen, disulfiram, and bronopol (Figure 1(C)). The fourth compound, thiram – another thiuram disulfide, was excluded from this study.

**The irreversible inhibition of IMPDH by disulfiram and bronopol**

The inhibitory activity of the hit compounds was analyzed for both CpIMPDH and hIMPDH II. The characterization of the kinetic parameters of CpIMPDH and hIMPDH II showed similar values to previous reports, with $K_m$ NAD$^+$ of 103 $\mu$M and $K_m$ IMP of 13.7 $\mu$M for CpIMPDH and $K_m$ NAD$^+$ 8.9 $\mu$M and $K_m$ IMP of 5.4 $\mu$M for hIMPDH II.$^8,15$

Determination of the inhibition mode was performed by dialysis, jump dilution, and incubation-time-dependent experiments (data not shown). Disulfiram and bronopol were identified as irreversible inhibitors to CpIMPDH and hIMPDH II. Subsequently, the time-dependent inactivation of IMPDH in the presence of various inhibitor concentrations was fitted into Equation (1) (Figure S2). The acquired $k_{obs}$ values were then fitted into Equation (2) (Figure 2). Both compounds were found to be potent inhibitors of IMPDH, compared to other known irreversible IMPDH inhibitors (Table 1). However, both inhibitors also showed a limited selectivity between mammalian and protozoan IMPDH with $k_{on}$ CpIMPDH:hIMPDH II value of 0.78 and 3.1 for disulfiram and bronopol, respectively. Inhibition of IMPDH by disulfiram and bronopol showed linear $k_{obs}$ plots, which indicated a one-step inactivation mechanism.

The substrate protection experiments showed that the higher concentration of IMP more strongly protect IMPDH from inactivation than higher concentration of NAD$^+$, which implies that these inhibitors target the IMP binding site of IMPDH. Molecular docking simulations of disulfiram and bronopol to hIMPDH II crystal provided the prediction of the enzyme–inhibitor interaction in the IMP binding site (Table S1; Figure S4).

**The mixed mode IMPDH inhibition by ebselen**

Ebselen showed a quite different inhibition property compared with the other two inhibitors. Ebselen did not exhibit any reversibility against CpIMPDH, even after decreasing the amount of enzyme and extending the measurement time (Figure S3). Therefore, inhibition of CpIMPDH by ebselen was then treated as a reversible mode. The acquired initial velocity values in the absence and presence of inhibitor were fitted into Equations (3) and (4). Ebselen inhibition of CpIMPDH was found to be noncompetitive in respect to NAD$^+$ and mixed in respect to IMP (Figure 3(A,B)). The noncompetitive inhibition against NAD$^+$ is a common characteristic of IMP binding site inhibitors. However, mixed-
model inhibition in respect to IMP illustrated the complexity of ebselen interaction to the IMP binding site. The fitted $K_{\text{is}}$ value was much lower than the $K_{\text{ii}}$ value, indicating a higher affinity of ebselen to free enzymes rather than to enzyme–substrate complexes (Table 2). Taken together, the result indicated that ebselen is a reversible IMP binding site inhibitor of CpIMPDH.

In contrary, ebselen showed a potent irreversible inhibition to hIMPDH. Different from the previous inhibitors, the plot of $k_{\text{obs}}$ versus ebselen concentration was found to be hyperbolic. Forcing this plot into Equation (2) yielded $k_{\text{on}}$ value of $9.3 \times 10^4 \text{M}^{-1} \text{s}^{-1}$ (Figure 3(C); Table 1). Substrate protection experiment and molecular modeling study suggested the higher affinity of ebselen to IMP binding site in the interaction with IMPDH (Table S2; Figure S4).

**Discussions**

The discovery of novel irreversible IMPDH inhibitors is very important due to its role as a drug target for the management of chronic conditions such as immunosuppressive, antiviral, and antineoplastic therapy. These therapies might need an extended therapeutic duration that theoretically could be provided by irreversible inhibitors due to its nonequilibrium inhibitory mechanism16,17.

Assigning new targets for known bioactive compounds is a vital process for significantly reducing financial and temporal burden of a drug discovery process. In this study, a HTS system was developed to screen novel inhibitors against IMPDHs from a library of known compounds.

From the screening process, three compounds were identified as irreversible inhibitors of IMPDH: disulfiram, bronopol, and ebselen. Disulfiram has been known as an alcohol aversion drug which acts as inactivator of acetaldehyde dehydrogenase. Intake of disulfiram together with alcohol resulted in the accumulation of acetaldehyde, causing discomforting symptoms thus discouraging further intake18. Bronopol was utilized as antiseptic and antifungal compound in aquatic veterinary settings and preservative in cosmetic products19,20. Ebselen has been known as a compound with broad activities, such as anti-inflammatory, anti-atherosclerotic, antibacterial, and anticancer. This compound has also been subjected into clinical trials for acute ischemic stroke and prophylactic neuroprotective21–27. Each inhibitor was reported previously as an irreversible inhibitor of cysteine, although with other different target enzymes19,20,28–31. Therefore, this study is the first report on the compounds as IMPDH inhibitors.
Previously, some research groups have identified several potent irreversible inhibitors, which targeted the unique cysteine residue in the IMP binding site of IMPDH. However, most of the irreversible inhibitors, if not all, are of IMP analogs\textsuperscript{32–34}. As the previous inhibitors, the hits from this study also seemed to target the same cysteine residue for their inhibition (Tables S1 and S2). Additionally, pre-incubation of these hit compounds with DTT or GSH before the inhibition assay attenuated their inhibitory activity (data not shown). Taken together, these experiments implied that the inhibition of IMPDHs by these hit compounds was also by cysteine modification. By considering their distinctive structures, this study is also the first reported IMP binding site inhibitors with structures other than IMP analogs\textsuperscript{1,35}.

Disulfiram and bronopol were found to have similar potency and inhibition mechanism in the inhibitory assay. Both exhibited similar high \(k_{\text{on}}\) values, comparable to those of potent irreversible IMPDH inhibitors EICARM and 2-FVIMP. However, selectivity of disulfiram and bronopol between mammalian and bacterial IMPDH seemed to be weak. Recently, disulfiram has been reported as an anticancer compound by inhibition of NPL4, an adaptor of p97 segregase\textsuperscript{36}. As hIMPDH II is also overexpressed in various cancer cells, it is possible that IMPDH inhibition by disulfiram might play a role for the observed antineoplastic activities\textsuperscript{1,37–40}.

Unlike the above two inhibitors, IMPDH inhibition by ebselen was quite intriguing. The mode of IMPDH inhibition by ebselen seemed to be of a mixed-model inhibitory mechanism that changes from a reversible mode to an irreversible mode depending on the concentration of the compound. Incubating hIMPDH II in the presence of ebselen showed the clear decay of enzymatic activity. Interestingly, subsequent \(k_{\text{on}}\) plotting yielded an unconventional hyperbolic curve fit. Lower concentration of inhibitor might have reversible inhibition as the main mode, hence the low \(k_{\text{obs}}\) value, and the irreversible inhibition mode progressively became more dominant as the inhibitor concentration increase. Ebselen begins to irreversibly inactivate hIMPDH II at a concentration around 0.5 \(\mu\)M, and is the most potent irreversible inhibitor of IMPDH reported to date.

As for CpIMPDH, the irreversibility of inhibition was not observed in the respective assay concentration. However, irreversible inhibition was observed in CpIMPDH after the incubation with ebselen in the submillimolar level, and dialysis was unable to restore the activity of the enzyme. Ebselen begins to irreversibly inactivate hIMPDH II at a concentration around 0.5 \(\mu\)M, and is the most potent irreversible inhibitor of IMPDH reported to date.

There are at least three possible explanation for this: First, that there are substantial differences of binding sites between IMPDHs in regards to ebselen binding, the second, that ebselen has a critical concentration threshold that triggers the chemical reactivity with cysteine residues if trespassed, and the third, that ebselen is a very slow tight-binding inhibitor of CpIMPDH\textsuperscript{13}. To confidently confirm the actual basis of this unique modal alteration, further experiments such as crystallization studies in different ratio of enzyme–inhibitor concentration are necessary. The ambivalence inhibition mode of ebselen has also been reported by other researchers.
research groups. Nevertheless, this study is the first report on
the alteration of ebseelen inhibition mode from a reversible mode
into an irreversible mode in a single dose-dependency plot.

Interestingly, the hit compounds also inhibited guanosine 5’-
monophosphate reductase (GMPR) of T. congolense, another
enzyme in the same purine nucleotide biosynthesis pathway
(Figure S5). Similar to IMPDH, GMPR has also been reported to
be dependent on catalytic cysteine for its activity. Therefore, it
is possible that the hit compounds act as dual IMPDH-GMPR
inhibitors. The decay of enzymatic activity of GMPR was not
observed during the time-dependent activity assay, suggesting a
reversible inhibition in T. congolense GMPR. Inhibition to GMPR
is important in order to completely disrupt the salvage purine
nucleotide biosynthesis, since GMPR could act as a surrogate
enzyme of IMPDH in the presence of ammonia.

The discovery of these irreversible inhibitors has opened the
possibility of future utilization of these compounds as chemothera-
peutical options for treating various IMPDH-related diseases. As
a proof-of-concept experiment, a preliminary efficacy assay of
disulfiram and bronopol in C. parvum-infected severe combined
immunodeficiency (SCID) mice was conducted. It was reported
before that inhibitor of CpiIMPDH could inhibit the growth of the
parasite. Both disulfiram and bronopol showed a clear inhibitory
activity to C. parvum growth with 48 and 30% decrease of parasite
burden compared to the control group, respectively. Bronopol,
however, showed significant toxicity, and one mouse died in the
day 5 of the experiment (Figure S6). In other reports, selenium
and ebseelen have also been found to effectively inhibit the growth
of C. parvum. Other experiments are currently ongoing to validate
this result. Nevertheless, these results have forecasted the possibility
of these hit compounds to be utilized as chemotherapeutic agents
for other IMPDH-dependent diseases. To support this proposed
utilization, further study is necessary to determine IMPDH
resynthesis rate in various therapeutic conditions.

In conclusion, three known compounds have been repurposed
as irreversible IMPDH inhibitors: disulfiram, bronopol, and ebseelen.
The compounds potently inhibit both mammalian and microbial
IMPDH in this study, thus could be utilized in various therapeutic
settings upon optimization of effective in vivo dosing. The variety
of reactive moieties in these compounds certainly provides benefi-
cial information for future structure–activity relationship study of
IMPDH binding site inhibitors. While the concentration of disulfiram
and bronopol used in the preliminary in vivo anti-cryptosporidiosis
experiment was high, the positive results suggest that the inhibitors
could also be explored as antimicrobial agents in combina-
torial therapy in a lower concentration, especially for targeting
GSH-lacking Gram-positive bacteria such as H. pylori, M. tubercu-
losis, S. aureus, B. subtilis. However, the efficacy of the hit com-
ounds should also be evaluated for other therapeutic indications
of IMPDH inhibitors, such as anticancer, immunosuppression, and
antiviral therapy. Special care should be given to bronopol, which
showed significant toxicity in the in vivo assay. Characterization of
other IMPDH inhibitors from our novel compound library and more
comprehensive in vivo study are currently ongoing.

Acknowledgements

We thank Professor Lizbeth Hedstrom (Brandeis University, USA)
for providing plasmids for expression of hIMPDH II. We thank
Professor Noboru Inoue (Ohihiro University of Agriculture and
Veterinary Medicine, Japan) for providing plasmids for expression
of CpiIMPDH and TcGMPR.

Disclosure statement

The authors declare that there is no conflict of interest.

Funding

This work was partly supported by Platform Project for Supporting
Drug Discovery and Life Science Research (Basis for Supporting
Innovative Drug Discovery and Life Science Research (BINDS)) from
AMED under Grant Number 18am0101093j0002, Hokkaido University,
Global Facility Center (GFC), Pharma Science Open Unit (PSOU),
funded by MEXT under “Support Program for Implementation of New
Equipment Sharing System” and Takeda Science Foundation.

ORCID

Makoto Ubukata http://orcid.org/0000-0001-8911-2815

References

1. Hedstrom L. IMP dehydrogenase: mechanism of action and
inhibition. Chem Rev 2009;109:2903–28.
2. Ratcliffe AJ. Inosine 5’-monophosphate dehydrogenase
inhibitors for the treatment of autoimmune diseases. Curr
Opin Drug Discov Devel 2006;9:595–605.
3. Franchetti P, Grifantini M. Nucleoside and non-nucleoside
IMP dehydrogenase inhibitors as antitumor and antiviral
agents. Curr Med Chem 1999;6:599–614.
4. Tong X, Smith J, Bukreyeva N, et al. Merimepobib, an IMPDH
inhibitor, suppresses replication of Zika virus and other
emerging viral pathogens. Antiviral Res 2018;149:34–40.
5. Pua KH, Stiles DT, Sowa ME, Verdine GL. IMPDH2 is an intracel-
ular target of the cyclophilin A and sanglifehrin A complex.
Cell Rep 2017;18:432–42.
6. Suganuma K, Sarwono AEY, Mitsuhashi S, et al. Myco-
phenolic acid and its derivatives as potential chemothera-
peutical agents targeting inosine monophosphate dehydrogenase in Trypanosoma congolense. Antimicrob
Agents Chemother 2016;60:4391–3.
7. Mitsuhashi S, Takenaka J, Iwamori K, et al. Structure–activity
relationships for inhibition of inosine monophosphate
dehydrogenase and differentiation induction of K562 cells
among the myco phenolic acid derivatives. Bioorganic Med
Chem 2010;18:8106–11.
8. Umejiego NN, Li C, Riera T, et al. Cryptosporidium parvum
IMP dehydrogenase - identification of functional, structural,
and dynamic properties that can be exploited for drug
design. J Biol Chem 2004;279:40320–7.
9. Oprea TI, Mestres J. Drug repurposing: far beyond new tar-
gets for old drugs. Aaps J 2012;14:759–63.
10. Bessoff K, Sateriale A, Lee KK, Huston CD. Drug repurposing
screen reveals FDA-approved inhibitors of human HMG-CoA
reductase and isoprenoid synthesis that block Cryptosporidium
parvum growth. Antimicrob Agents Chemother 2013;57:
1804–14.
11. Andrews KT, Fisher G, Skinner-Adams TS. Drug repurposing
and human parasitic protozoan diseases. Int J Parasitol Drugs Drug Resist 2014;4:95–111.
12. Baici A. Slow-onset enzyme inhibition and inactivation. Exp
Stand Cond Enzym Charact 2013;55–74.
1. Morrison JF, Walsh CT. The behavior and significance of slow-binding enzyme inhibitors. Adv Enzymol Relat Areas Mol Biol. 1988;61:201–301.

2. Zhang J-H, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67–73.

3. Wang W, Hedstrom L. Kinetic mechanism of human inosine 5′-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products. Biochemistry 1997;36:8479–83.

4. Singh J, Petter RC, Baille TA, Whitty A. The resurgence of covalent drugs. Nat Rev Drug Discov 2011;10:307–17.

5. Bauer RA. Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies. Drug Discov Today 2015;20:1061–73.

6. Tewari R, Sharma V, Sk UH, et al. Ebselen abrogates TNF death inducing signaling complex. Int J Cancer 2008;123:645–7.

7. Zhang J-H, Chung TDY, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67–73.

8. Wang W, Papov VV, Minakawa N, et al. Inactivation of inosine 5′-monophosphate dehydrogenase by the antiviral agent 5-ethyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5′-monophosphate. Biochemistry 1996;35:95–101.

9. Pal S, Bera B, Nair V. Inhibition of inosine monophosphate dehydrogenase (IMPDH) by the antiviral compound, 2-vinylinosine monophosphate. Bioorganic Med. Chem. 2002;10:3615–8.

10. Skrott Z, et al. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 2017;552:194–9.

11. Fellenberg J, Kunz P, Sahr H, Depeweg D. Overexpression of inosine 5′-monophosphate dehydrogenase type II mediates chemoresistance to human osteosarcoma cells. PLoS One 2010;5: e12179.

12. Barnes BJ, Izydore RA, Eakin AE, Hall IH. Induction of Tmol4 leukemia cell death by 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2-4-diones: specificity for type II inosine 5′-monophosphate dehydrogenase. J Pharmacol Exp Ther 2001;298:790–6.

13. Chen L, Pankiewicz KW. Recent development of IMP dehydrogenase inhibitors for the treatment of cancer. Curr Opin Drug Discov Devel 2007;10:403–12.

14. Xu Y, et al. High expression of IMPDH2 is associated with aggressive features and poor prognosis of primary nasopharyngeal carcinoma. Sci Rep 2017;7:745.

15. Mukherjee S, Weiner WS, Schroeder CE, et al. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication. ACS Chem Biol 2014;9:2393–403.

16. Balther M, Holzhütter H-G, Kuban RJ, et al. The inhibition of mammalian 15-lipoxygenases by the anti-inflammatory drug ebselen: dual-type mechanism involving covalent linkage and alteration of the iron ligand sphere. Mol Pharmacol 1999;56:196–203.

17. Weglarz-Tomczak E, Burda-Grabowska M, Giurj M, et al. Identification of methionine aminopeptidase 2 as a molecular target of the organoselenium drug ebselen and its derivatives/analogues: Synthesis, inhibitory activity and molecular modeling study. Bioorganic Med. Chem. Lett 2016;26:5254–9.

18. Sarwono AEY, et al. Identification and characterization of guanosine 5′-monophosphate reductase of Trypanosoma congolense as a drug target. Parasitol Int 2017;66:537–44.

19. Patton GC, Stenmark P, Gollapalli DR, et al. Cofactor mobility determines reaction outcome in the IMPDH and GMPR (β-β) barrel enzymes. Nat Chem Biol 2011;7:950–8.

20. Smith S, Boitz J, Chiadamaram ES, et al. The cystathionine-β -synthase domains on the guanosine 5′-monophosphate reductase and inosine 5′-monophosphate dehydrogenase enzymes from Leishmania regulate enzymatic activity in
response to guanylate and adenylate nucleotide levels. Mol. Microbiol 2016;100:824–40.

47. Gorla SK, McNair NN, Yang G, et al. Validation of IMP dehydrogenase inhibitors in a mouse model of cryptosporidiosis. Antimicrob Agents Chemother 2014;58:1603–14.

48. Eltahan R, Guo F, Zhang H, et al. Discovery of ebselen as an inhibitor of Cryptosporidium parvum glucose-6-phosphate isomerase (CpGPI) by high-throughput screening of existing drugs. Int J Parasitol Drugs Drug Resist 2018;8:43–9.

49. Huang K, Yang S. Inhibitory effect of selenium on Cryptosporidium parvum infection in vitro and in vivo. Biol Trace Elem Res 2002;90:261–72. [pii] r10.1385/BTER:90:1-3:261

50. Lu J, Vlamis-Gardikas A, Kandasamy K, et al. Inhibition of bacterial thioredoxin reductase: an antibiotic mechanism targeting bacteria lacking glutathione. Faseb J 2013;27:1394–403.

51. Fahey RC, Brown WC, Adams WB, et al. Occurrence of glutathione in bacteria. J Bacteriol 1978;133:1126–9.